[Treatment of benign prostatic hyperplasia. Results of a treatment study with the phytogenic combination of Sabal extract WS 1473 and Urtica extract WS 1031 in urologic specialty practices].
In an open, prospective, multicentric observational study involving 419 specialist urological practices, the efficacy and tolerability of a combination preparation comprising Sabal extract WS 1473 and Urtica extract WS 1031 were investigated in 2080 patients with Alken's stage I or II benign prostatic hyperplasia. A before-and-after comparison revealed an improvement in the pathological findings and in the obstructive and irritative symptoms. For the most part, the efficacy and tolerability of the preparation were assessed by the physician to be "very good" or "good". At the end of treatment, most patients indicated an improvement in their prostatic symptomatology and in general quality of life. Fifteen patients (0.72%) were suspected of having developed mild side effects.
Schneider
H J
HJ
Medizinisch-Wissenschaftliche Abteilung, Dr. Willmar Schwabe Arzneimittel, Karlsruhe.
Honold
E
E
Masuhr
T
T
D058891:5-alpha Reductase Inhibitors; D000368:Aged; D047072:Aromatase Inhibitors; D004338:Drug Combinations; D006801:Humans; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000627:therapeutic use*; D011467:Prostate / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
D058891:5-alpha Reductase Inhibitors; D047072:Aromatase Inhibitors; D004338:Drug Combinations; D010936:Plant Extracts